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NeuroprotectionParkinson’s disease (PD) displays a greater prevalence and earlier age at onset in men. This review
addresses the concept that sex differences in PD are determined, largely, by biological sex differences
in the NSDA system which, in turn, arise from hormonal, genetic and environmental inﬂuences. Current
therapies for PD rely on dopamine replacement strategies to treat symptoms, and there is an urgent,
unmet need for disease modifying agents. As a signiﬁcant degree of neuroprotection against the early
stages of clinical or experimental PD is seen, respectively, in human and rodent females compared with
males, a better understanding of brain sex dimorphisms in the intact and injured NSDA system will shed
light on mechanisms which have the potential to delay, or even halt, the progression of PD. Available evi-
dence suggests that sex-speciﬁc, hormone-based therapeutic agents hold particular promise for develop-
ing treatments with optimal efﬁcacy in men and women.
 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).1. Introduction
One’s sex is increasingly recognised as a factor which inﬂuences
the incidence and/or nature of all major complex diseases, includ-
ing neurodegenerative and neuropsychiatric disorders. This, in
turn, may be determined by biological sex differences in brain
organisation, structure and function, which are determined genet-
ically and epigenetically (Gabory et al., 2009; Kaminsky et al.,
2006; McCarthy et al., 2009; Cahill, 2006). This review will con-
sider these phenomena in relation to Parkinson’s disease (PD),
numerous aspects of which strongly support the urgent need for
a better understanding of brain sex dimorphisms in the intact
and injured brain, in order to design improved therapies with opti-
mal efﬁcacy in male and female patients alike.
2. Parkinson’s disease: differences between men and women
2.1. Aetiology and pathology of PD
PD is the second most common neurodegenerative disorder,
affecting approximately 0.3% of people in the developed world.
This rises rapidly to 3% for individuals over the age of 65 years,
to demonstrate that advanced age comprises a major risk factor
(Dexter and Jenner, 2013). In addition, such ﬁgures highlight the
increasing burden that treatment of PD place on health care sys-
tems worldwide, as the population life-expectancy increases inseveral countries. Clinically, PD is a movement disorder that is
characterised by motor symptoms such as bradykinesia with rigid-
ity, tremor at rest, gait disturbances and difﬁculty in swallowing
and producing speech. Non-motor symptoms associated with the
disorder include anxiety, depression, insomnia, dementia, auto-
nomic dysfunction and constipation, which can often reduce pa-
tients’ quality of life even more signiﬁcantly than motor aspects
(Weintraub et al., 2008; Jenner et al., 2013). A major pathological
lesion associated with PD is the loss of midbrain dopaminergic
(DAergic) neurons in the substantia nigra pars compacta (SNc)
and the consequent loss of DA input to the caudate nucleus and
putamen (the striatum). This nigrostriatal DA (NSDA) pathway
plays a central role in regulating ﬁne motor control, and its degen-
eration thus leads to the primary motor symptoms of PD. In up to
approximately 10% of cases, rare familial genetic mutations have
been identiﬁed as causing PD. However the vast majority of cases
are of unknown cause and are termed idiopathic or sporadic (Klein
and Schlossmacher, 2007). Yet, studies have begun to cast light on
the cellular and molecular processes which may underlie the
degeneration of the NSDA system. Putative pathological substrates
include but are not limited to mitochondrial dysfunction (Vives-
Bauza et al., 2010; Pienaar and Chinnery, 2013) accompanied by
the excessive production of radical oxygen species (Mattson,
2006), the formation of protein aggregates, termed Lewy
bodies(principally composing of a-synuclein and ubiquitin) within
the surviving DAergic neurons and microglial inﬂammation (Hall-
iday and Stevens, 2011). Collectively, these observations support
the general concept that PD is a complex disease, representing a
clinical syndrome with an aetiology that is likely to comprise of
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the immune system and aging (Jenner et al., 2013; Klein and Sch-
lossmacher, 2007).
2.2. Sex differences in PD
After aging, epidemiological studies have revealed the male sex
as a prominent risk factor for developing PD at all ages and for all
nationalities studied. Reports of male to female ratios for incidence
rates vary from 1.37 to 3.7 (Baldereschi et al., 2000; Swerdlow
et al., 2001; Van Den Eeden et al., 2003; Wooten et al., 2004; Shul-
man and Bhat, 2006; Taylor et al., 2007), with a large meta-analysis
study suggesting that, in any speciﬁc time-frame, twice as many
men than women suffer from PD (Elbaz et al., 2002).
2.2.1. Clinical proﬁle of PD
In addition to differences in its prevalence in men and women,
many studies have reported sex differences in the clinical proﬁle of
PD. For example, some studies report that the age of onset of PD is
approximately 2 years later in women compared with men (Haax-
ma et al., 2007; Alves et al., 2009). Although earlier work con-
tradicted this ﬁnding (Baba et al., 2005), such discrepancies can
be explained, at least in part, by sex differences in disease presen-
tation. For example, several studies suggest that females present
with a milder PD phenotype, which is most notable in the early
clinical stages, especially prior to the introduction of anti-parkinso-
nian medication (Shulman and Bhat, 2006; Haaxma et al., 2007;
Miller and Cronin-Golomb, 2011). Compared to men, women are
also reported to present more often with tremor, a symptom that
correlates both with a later age of onset and a slower rate of de-
cline of motor impairment (Haaxma et al., 2007). Other symptoms
that were found to be more prevalent in women than in men in-
clude nervousness, sadness, depression and constipation, whereas
men suffered more from daytime sleepiness, dribbling and sex-re-
lated symptoms (Martinez-Martin and Falup, 2012). Rigidity and
rapid eye movement behaviour disorder occurs more frequently
in men, whereas women are more likely to have dyskinesias and
PD-associated depression than men (Martinez-Martin and Falup,
2012). A sex-speciﬁc pattern is also emerging for PD-associated
cognitive changes, with deﬁcits in verbal ﬂuency and recognition
of facial emotions being more prevalent in men, whilst a reduction
in visuospatial cognition occur more frequently in women (Miller
and Cronin-Golomb, 2011). Additionally, the efﬁcacy, tolerability
and pharmacokinetics of drugs used for treating PD appear to differ
in men versus women (Shulman and Bhat, 2006).
In support of the notion that sex differences in disease suscep-
tibility may be determined, at least in part, by biological sex differ-
ences in various affected brain regions, a number of differences in
motor and sensory functions, which rely on the NSDA system have
been noted in healthy men and women. For example, in tests of
ﬁne motor control and speech articulation, women generally out-
perform men (Jennings et al., 1998). The advent of real-time
in vivo imaging techniques also provides direct evidence for innate
differences in NSDA transmission in men and women. These in-
clude differences in basal striatal DAergic neuron dynamics (Pohj-
alainen et al., 1998; Lavalaye et al., 2000; Kaasinen et al., 2001;
Mozley et al., 2001; Laakso et al., 2002), amphetamine-stimulated
DA release (Munro et al., 2006) and sex-related differences in the
functional relationship between regional DA release and motor
performance, affect and cognitive function (Mozley et al., 2001;
Riccardi et al., 2011). Sex differences in the healthy NSDA system
are further corroborated by evidence discussed below from gene
proﬁling studies (Section 2.2.2) and the discovery that the SRY gene
(sex determining region on the Y sex chromosome) is expressed in
SNc DA neurons in humans (Section 2.3.1) as well as rodents
(Section 6.1).2.2.2. Molecular pathology of PD
New technologies which enable dissection of the molecular
pathology of PD are beginning to provide a more objective analysis
of underlying sexual dimorphisms. For example, the SNc DAergic
neurons are identiﬁable in post-mortem brains, due to their dark
neuromelanin pigmentation. This uniquely enables single-cell laser
capture micro-dissection of this neuronal population, and has been
coupled with microarray analysis of DNA in order to investigate
gene expression proﬁles obtained from post-mortem brains of con-
trol subjects with individuals who, in life, had been diagnosed with
late-stage idiopathic PD (Simunovic et al., 2011; Cantuti-Castelve-
tri et al., 2007). In the normal brain, genes involved in signal trans-
duction and neuronal maturation were up-regulated in women,
whereas genes implicated in PD pathogenesis, when harbouring
speciﬁc mutations (e.g. a-synuclein and PINK-1), were up-regu-
lated in men. In the DAergic neurons surviving in PD-affected
brains, changes in the expression of genes encoding for protein ki-
nase activity and genes associated with proteolysis and Wnt sig-
nalling predominated in women, whereas predominant
expressional changes for genes involved in protein- and copper-
binding activities occurred in men (Simunovic et al., 2011; Cantu-
ti-Castelvetri et al., 2007). These studies demonstrate that gene
expression proﬁles in normal SNc DAergic neurons are sex-speciﬁc
and suggest a bias in males which may underlie the predisposition
to develop PD. They also indicate that adaptive processes in the
surviving DAergic neurons proceed via different mechanisms in
males and females, suggesting that the nature of the disease, and
potentially the response to treatment, may be sex-speciﬁc.
Collectively, clinical and molecular studies clearly support the
notion that women are relatively protected from PD compared
with men. They also underscore the need for a better knowledge
of the basis of sex differences in PD. Investigations into the patho-
physiology underlying sex differences in the presentation, progres-
sion and treatment responses in PD are in their infancy, but offer
considerable potential for improving clinical assessment and treat-
ment of the disease.2.3. Genetic and epigenetic factors contributing to sex bias in PD
The inﬂuence of genetic and epigenetic factors underlying dis-
ease is a vast subject, and this section will brieﬂy focus only on
areas of relevance to sex differences in PD. Environmental factors,
which can alter the epigenetic signature, shall be considered, and
in this context, sex and sex hormones, as well as stress and stress
hormones, can be included as environmental factors since hor-
monal effects include DNA methylation and histone modiﬁcations,
thereby altering epigenetic regulation of autosomal genes and
potentially inﬂuencing differential susceptibility to complex dis-
eases (Kaminsky et al., 2006).2.3.1. Genes
The genetics of PD is a rapidly growing ﬁeld. To-date, mutations
in at least 17 different genes have been identiﬁed as the cause of
the rare familial forms of the disease (Dexter and Jenner, 2013).
These genes often encode proteins that are associated with molec-
ular pathways that are affected in sporadic forms of the disease.
For example, mutations in the gene encoding a-synuclein accounts
for only a very small proportion of familial PD. Yet protein aggre-
gations containing a-synuclein (Lewy bodies) comprise a diagnos-
tic pathology related to the ﬁnal stages of DA neuronal loss in
idiopathic PD and indicate altered protein aggregation as a contrib-
utory cause. Other mutations causing familial variants of PD in-
volve genes that protect against mitochondrial dysfunction
(PINK-1) and oxidative stress (DJ-1), all of which are pathological
processes that have been implicated in idiopathic PD. However,
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ences in PD.
In view of the evidence that estrogen may be neuroprotective, a
small number of studies have investigated the relationship be-
tween single nucleotide polymorphisms (SNPs) in estrogen-related
genes and the onset and development of PD (see Sections 2.3.3 and
4). Although some authors have suggested a complex association,
which may be more prevalent in one sex over the other (Palacios
et al., 2011; Chung et al., 2011), no clear correlations have been re-
ported to exist between SNPs in estrogen receptors (ERs) and the
prevalence of PD. Some studies have shown, however, that genetic
variation in ERbwas associated with an early-age (between ages 20
and 50 years) onset of PD (Westberg et al., 2004; Hakansson et al.,
2005; Maraganore et al., 2002), which accounts for around 10% of
all cases (Dexter and Jenner, 2013). However, it remains to be
determined how SNPs inﬂuence disease risk (Klein and Schlossm-
acher, 2007). Such explorations generally require interrogation
on a large scale, taking into account several environmental factors
and demographic characteristics, as well as the difﬁculties inherent
in detecting the small effects of common genetic variants in popu-
lation-based, case-controlled studies. In this regard, as single-gene
effects account for so few PD cases, other factors must account for
sex differences.
Evidence in humans and other species (see Section 6.1) suggests
that the sex chromosomes themselves are likely contributors to
biological sex differences and could potentially inﬂuence sex bias
in many common, complex diseases (Kaminsky et al., 2006). This
could be due to a direct effect of Y chromosome genes (present
only in males), or to incomplete silencing of X chromosome genes
in XX-chromosome containing females, as well as sex differences
in the genomic imprinting of X-chromosome genes (Federman,
2006; van Nas et al., 2009; Arnold and Burgoyne, 2004). One Y
chromosome gene in particular, SRY, may be of relevance to NSDA
function and, possibly also to PD. The actions of this gene were
classically thought to be restricted to sex determination early in
development due to its role in directing formation of the testes,
but its expression during development and adulthood has now
been identiﬁed in a number of male non-reproductive tissues,
including the brain in humans (Ngun et al., 2011), rats and mice
(see Section 6.1) (Dewing et al., 2006). Moreover, investigations
done on human post-mortem brain specimens, revealed SRY
immunoreactivity (IR) co-localised with a sub-population of SNc
neurons that express tyrosine hydroxylase (TH). As TH is the
rate-limiting step in DA synthesis, this identiﬁes the SRY-IR neu-
rons as belonging to the NSDA population (Czech et al., 2012).
Using retinoic acid-induced differentiation of human male-derived
precursor NT2 cells into DA cells, the same study conﬁrmed co-
localisation of SRY and TH. Furthermore, it was shown that SRY
positively regulated expression of enzymes involved in the regula-
tion of DA synthesis (TH, DOPA decarboxylase and dopamine b-
hydroxylase) and metabolism (monoamine oxidase A) in the M17
cell line derived from a male neuroblastoma. These ﬁndings sup-
port the view that the male NSDA system is uniquely regulated
by SRY. Future studies are needed to determine whether this con-
tributes to the molecular and functional sex differences inherent to
this pathway (see Section 2.2), and to elucidate on the role of SRY
in the development of midbrain DA-related disorders that show a
sex bias, such as PD.
2.3.2. Life-style
Sex differences in life-style may also be contributory factors to
the sex differences seen in PD, which could interact with a genetic
predisposition (Wooten et al., 2004; Das et al., 2011), supporting
the multiple-hit hypothesis for developing PD (Carvey et al.,
2006). For example, exposure to herbicides (such as paraquat)
has been associated with an increased risk for PD; as men weretraditionally more likely to be agricultural workers, occupational
exposure to agrichemicals could introduce differential risk expo-
sure in men compared to women (Semchuk et al., 1992). Equally,
head trauma has been linked to an increased risk for men to devel-
op PD. In this regard, men show increased likelihood to suffer trau-
matic brain injury due to their greater exposure to events such as
road trafﬁc accidents or contact sports (Bruns and Hauser, 2003;
Lehman et al., 2012).
Although there is not yet any conclusive evidence for a direct
relationship, exposure to emotionally stressful events is another
environmental factor which could increase the likelihood for
developing PD. Stressful experiences compromise striatal DA re-
lease and motor function in healthy men and women (Cahill,
2006; Mozley et al., 2001), and can also exacerbate motor symp-
toms in PD patients (Macht et al., 2005). Additionally, poor strate-
gies for coping with emotional stress may impact negatively on of
life in PD (Whitworth et al., 2013), whilst an accumulation of
stressful life events does appear to contribute to PD risk (Clark
et al., 2013). Emerging evidence demonstrates that responses to,
and strategies for coping with emotional or psychogenic stress dif-
fer notably in men (typiﬁed as the ‘fright, ﬁght or ﬂight’ response)
and women (typiﬁed as the ‘tend and befriend’ response) (Klein
and Corwin, 2002; Kudielka and Kirschbaum, 2005). Indeed, sex
differences in terms of responses to stressful events are identiﬁable
from functional magnetic resonance imaging (fMRI) data. In this
regard, Wang and colleagues (2007) reported that men’s and wo-
men’s responses to a mild/moderate stressor could be distin-
guished to a very high accuracy based on real-time in vivo brain
imaging alone (Wang et al., 2007). Additionally, biological differ-
ences between men and women have been noted as a major factor
for consideration in the impact of stress on brain structure, func-
tion and pathology (Lupien et al., 2009). Taken together, underly-
ing sex differences in stress-responsive circuitry are further
contenders for contributing differential male/female risk factors
for developing PD.
2.3.3. Sex hormones
Sex hormones are by far the most important factors for driving
structural and functional sexual differentiation in the brain, whilst
also being critical drivers of sex differences in disease susceptibil-
ity. In studies focusing on such aspects, most attention has focused
on estrogens, especially on 17b-estradiol (E2), the most abundant,
naturally occurring estrogen in non-pregnant mammals, which is
widely recognised to have neuroprotective actions and, therefore,
may confer the advantage in diseases where women generally fare
better, such as PD. The epidemiological and clinical evidence for E2
neuroprotection against PD in women has been the subject of a
number of in-depth reviews (Shulman and Bhat, 2006; Dluzen
and Horstink, 2003; Liu and Dluzen, 2007; Bourque et al., 2009),
hence only the salient features will be summarised here. Women
who underwent bilateral oophorectomy before menopause have
an increased risk of developing PD (Benedetti et al., 2001;
Ragonese et al., 2006; Rocca et al., 2008). At menses, when estro-
gen levels are lowest, PD symptom severity may worsen (Quinn
and Marsden, 1986). Several reports also suggest that estrogen-
based hormone replacement therapy can relieve PD symptoms
when given in the early stages of the disease (Benedetti et al.,
2001; Saunders-Pullman et al., 1999; Tsang et al., 2000) and
decrease the risk of developing PD (Liu and Dluzen, 2007; Currie
et al., 2004), whereas PD symptoms may deteriorate on cessation
of therapy (Sandyk, 1989). However, there are some clinical
reports, albeit in the minority, which fail to ﬁnd evidence of estro-
gen neuroprotection (Popat et al., 2005). It should be borne in mind
that the majority of clinical studies have been retrospective, and
considerable variations in hormone replacement regimes, as well
as the duration of the period of hypo-estrogenicity in the women
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tion of study data (Wise et al., 2005). Larger scale, prospective, con-
trolled double-blind cross-over studies would be needed to reach
ﬁrm conclusions and, thus far, any interaction between sex hor-
mones and PD in men remains unexplored, although animal stud-
ies suggest potential detrimental effects of male gonadal factors
(see Section 4). Notably, however, sex differences in PD may re-
main after menopause (Schrag et al., 2000), suggesting that estro-
genic neuroprotection may be just one piece in the jig-saw puzzle,
by which sex differences seen in PD may be explained.
In summary, the evidence discussed thus far favours the view
that sex inﬂuences the normal functioning of the healthy NSDA
pathway, as well as the nature and incidence of the degenerative
processes affecting this pathway; sex hormones, speciﬁcally estro-
gens in females, seem to play a key role. Clinical studies are, how-
ever, limited in their ability to dissect the nature of estrogen’s
actions on the brain, and there is no experiment of nature analo-
gous to the menopause or menstrual cycle in women, to provide
clues about potential hormonal inﬂuences in men. Therefore, pre-
clinical experimental models of PD have an important role to play
for ﬁlling these information gaps.3. Sex differences in experimental Parkinson’s disease,
As the causes of PD are largely unknown, classical experimental
in vivo and in vitromodels of PD seek to mimic the prime patholog-
ical lesion associated with disease, namely NSDA degeneration
using selective neurotoxins (Pienaar et al., 2012); more recently,
genetic modiﬁcations of the genes identiﬁed as causing the rare
familial forms of PD have also been recreated in animal models
(Blesa et al., 2012). Although no single model perfectly recreates
all aspects of the disease, they have helped elucidate much of what
we know regarding the aetiology, pathology and molecular mech-
anisms of PD, whilst having been instrumental in developing new,
and optimising existing treatments.
3.1. Animal models
The toxin-based models have been used widely for the study of
sex differences and hormonal inﬂuences in PD. The most com-
monly used models involve central administration of 6-hydroxy-
dopamine (6-OHDA) directly to the NSDA pathway, mainly in
rodents (Dluzen, 1997; Murray et al., 2003), or systemic adminis-
tration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)
in mice and non-human primates (Dluzen and Horstink, 2003;
Miller et al., 1998), as well as centrally in non-human primates
(Fox and Brotchie, 2010; Morissette and Di Paolo, 2009). Both tox-
ins selectively kill DAergic cells through a combination of excessive
generation of oxidative stress and inhibition of mitochondrial res-
piration (Blum et al., 2001; Glinka et al., 1996; Simola et al., 2007).
Methamphetamine (MA) has also been used to create nigral lesions
in mice, although the similarities to parkinsonian degeneration
have been less well characterised (Dluzen et al., 2002; Dluzen
and Liu, 2008).
3.2. Sex differences
In studies using genetic animal models of PD, sex differences
have thus far received little attention. However, it was reported
that the higher expression of certain anti-apoptotic and anti-
oxidant molecules found in the striatum of female, wild-type mice
compared with males, was lost in parkin-null mice, as was the
ability of estradiol to stimulate neuroprotective mechanisms in
fetal DAergic neurons (Rodriguez-Navarro et al., 2008). Such obser-
vations provide clues as to the genetic-molecular processes whichappear to differ in males and females, and serve to caution against
drawing general conclusions from genetic models where only one
sex has been investigated.
Using toxin-induced models of PD, evidence from our own and
other laboratories shows that they are able to reproduce sex dif-
ferences in disease susceptibility seen in humans. For example,
2 weeks after administration of 1 lg 6-OHDA into the medial fore-
brain bundle, the depletion of both DA levels in the striatum and
loss of DAergic neurons in the SNc is signiﬁcantly greater in male
rats compared with females (Table 1 and Fig. 1 control groups)
(Murray et al., 2003; Gillies et al., 2004; McArthur et al., 2007).
The progressive loss of DAergic cells over a 5 week period post-
lesioning was also consistently greater in 6-OHDA-treated male
rats compared with females, conﬁrming a true sex difference
rather than a difference in the rate of neurodegeneration (Moroz
et al., 2003). Greater SNc and striatal lesions are also seen in male
mice compared with females after treatment with MPTP or MA
(Liu and Dluzen, 2007; Miller et al., 1998; Dluzen, 2000; Yu and
Liao, 2000). Importantly, these sex differences are present only
following partial lesions (<60%) of the NSDA pathway using mod-
erate concentrations of 6-OHDA (Gillies et al., 2004; Gillies and
McArthur, 2010a); however, when the lesion exceeds approxi-
mately 70–80%, sex differences are no longer apparent (Gillies
et al., 2004; Gillies and McArthur, 2010a) (Table 1). Collectively,
these pre-clinical ﬁndings corroborate the clinical studies which
suggest that females may be more able to resist the onset and/
or progression of neurodegenerative lesions. Moreover, they also
demonstrate that the degree of intrinsic neuroprotection in the fe-
male brain can be over-ridden once neurodegeneration reaches a
certain extent. Additionally, these studies demonstrate that the
use of an experimental regimen producing sub-maximal lesions
in the NSDA pathway, which is considered to be a model of pre-
clinical/early stage PD (Schwarting and Huston, 1996), holds po-
tential for investigating the factors that provide the female
advantage.4. Systemic sex steroid hormones and susceptibility in
experimental Parkinson’s disease
As might be predicted from clinical observations, most atten-
tion has focused on sex hormones as being the major factors driv-
ing sex differences in PD. Although males exhibit greater
susceptibility, the majority of studies centre on the neuroprotec-
tive effects of estrogens in females. However, the available evi-
dence indicates that gonadal factors also play a signiﬁcant, albeit
different, role in males (Gillies et al., 2004; McArthur et al., 2007;
Gillies and McArthur, 2010b), meriting separate consideration of
the sexes.4.1. Striatal lesions in females
Compared with gonad-intact female rats, the loss of striatal DA
induced by 6-OHDA is far greater in ovariectomised rats, and this
effect of gonadectomy can be reversed by replacement of estradiol
to physiological levels, prior to lesioning (Dluzen, 1997; Murray
et al., 2003; Ferraz et al., 2008) (Fig. 1A). Similar preservation of
striatal DA by estradiol in females can be demonstrated for NSDA
lesions produced by MPTP in mice (Dluzen and Horstink, 2003;
Miller et al., 1998) and in non-human primates (Morissette and
Di Paolo, 2009), as well as by MA in mice (Yu and Liao, 2000). Smal-
ler losses of striatal DA are also seen when any of these three toxins
are administered at the stage of the estrous cycle when estradiol
levels are maximal (proestrus), compared with administration
when circulating estradiol reaches a nadir (diestrus) (Dluzen and
Horstink, 2003; Yu and Liao, 2000; Datla et al., 2003). However,
Table 1
Sex differences in the 6-hydroxydopamine (6-OHDA) model of Parkinson’s disease.
MFB injection Striatal DA content % lesioned versus unlesioned side TH-IR cells % lesioned versus unlesioned side cells
Male Female Male Female
Vehice control 105.4 ± 9.8 100.3 ± 6.2 101.4 ± 8.9 98.6 ± 8.5
1 lg 6-OHDA 50.3 ± 4.8* 72.7 ± 6.7*,# 59.3 ± 4.5* 76.2 ± 2.5#
6 lg 6-OHDA 4.2 ± 0.3** 5.1 ± 0.3** 25.5 ± 8.3 15.7 ± 6.1
Male rats and female rats at proestrus received a 4 lL injection into the left medial forebrain bundle of either vehicle or a dose of 6-OHDA (1 lg or 6 lg) under general
anaesthesia. Two weeks later striatal tissue was collected for assessment of dopamine levels using high performance liquid chromatography coupled with electrochemical
detection; the hindbrains were also dissected and processed immunocytochemically for tyrosine hydroxylase (TH), the rate-limiting enzyme in dopamine synthesis, as a
marker of dopaminergic neurons, which were then counted. The left (lesioned) and right (unlesioned, control) striata and SNc were processed separately. Group means for the
lesioned and unlesioned sides were used to calculate the percentage survival of TH immunoreactive (IR) cells. 6-OHDA reduced striata DA levels and TH-IR cell numbers in the
SNc in a dose-dependent manner and a sex difference in the severity of the lesion was observed with the dose of 1 lg 6-OHDA. Values represent the mean ± s.e.m. (n = 6). Full
details in Murray et al. (2003).
* P < 0.05 for the effect of 6-OHDA versus vehicle.
** P < 0.01 for the effect of 6-OHDA versus vehicle.
# p < 0.05 compared with males.
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ity (Table 1) (Murray et al., 2003; Gillies et al., 2004), reminiscent
of the loss of advantage in the gonad-intact female with larger le-
sions (Cordellini et al., 2011). It would appear that this effect may
not be off-set by increasing the dose of estradiol, because replace-
ment in ovariectomised rats with levels exceeding the normal
physiological range failed to protect, and even exaggerated lesion
size (Bourque et al., 2009; Cordellini et al., 2011; Ramirez et al.,
2003). To date, the majority of studies discussed here replace
estrogens either at the time of ovariectomy or soon after, with evi-
dence to suggest that estrogen administered after creating the
NSDA lesion, failed to protect (Bourque et al., 2009; Datla et al.,
2003). Collectively, these studies suggest that the level of circulat-
ing estradiol prevailing at the time that the lesion is made is criti-
cal, and that physiological levels, whether endogenous or achieved
through exogenous administration, have protective capacity in the
partially injured female NSDA system. Therefore, this supports the
view that sex differences in PD could be attributable largely to the
protective effect of the gonadal factor, estradiol.4.2. Striatal lesions in males
In contrast to females, striatal DA loss induced by sub-maximal
doses of 6-OHDA was signiﬁcantly reduced in gonadectomised
male rats compared with gonad-intactmales (Fig. 1C) (Murray
et al., 2003). Although some studies in mice have not detected a
signiﬁcant effect of castration in neurotoxin-induced striatal DAer-
gic lesions (Dluzen et al., 1994; Yu and Wagner, 1994; Gao and
Dluzen, 2001), testosterone treatment of gonad-intact or gonadec-
tomised CD-1 male mice, worsened striatal DA loss in animals with
mild/moderate lesions (40%), but caused no further worsening
once the lesions were more extensive (70%) (Dluzen et al.,
1994; Lewis and Dluzen, 2008). On balance, these ﬁndings suggest
that, across species, testosterone has a detrimental effect in exper-
imental PD. However, similar to the protective effect of estradiol in
females, hormonal modulation is only seen under experimental
conditions that mimick the pre-clinical/early phases of the degen-
erative process. In our own studies, which investigated hormone
replacement in 6-OHDA-lesioned castrated rats, we found that
administration of the non-aromatisable androgen, dihydrotestos-
terone (DHT), failed to reverse the effects of gondectomy on striatal
DA loss, whereas estradiol treatment did (Fig. 1C). This result sug-
gests that circulating testosterone promotes NSDA degeneration in
male rats only after it is converted to estradiol by aromatase en-
zymes, which are expressed in many brain regions, including the
striatum (Kuppers et al., 2000). Data from male mice are moreequivocal, with reports that estradiol lacks protective effects
against MA toxicity (Gao and Dluzen, 2001; Yu et al., 2002),
whereas it may have protective effects against MPTP in males of
the highly susceptible C57Bl/6 mouse strain (Dluzen, 1996). Differ-
ences in strain, neurotoxin and hormonal treatment regimens are
therefore likely to contribute to the variability in the data obtained
regarding hormonal inﬂuences in male susceptibility for develop-
ing PD.
The preceding evidence from experimental models of PD sup-
ports the consensus view from clinical observations that ovarian
factors are protective in the female NSDA, whilst revealing that go-
nadal factors may be detrimental in males. This suggests that hor-
monal inﬂuences in both sexes compound to create differences in
susceptibility to striatal lesions. Furthermore, they identify estra-
diol as having dimorphic effects on striatal DA loss in experimental
PD in females (reduced striatal lesions) and males (increased stri-
atal lesions), highlighting that the reported clinical beneﬁts of
estrogens in the female sex may not simply translate to the oppo-
site sex.5. Hormonal mechanisms underpinning sex differences in
experimental PD
5.1. The DAT hypothesis
A number of studies suggest that the DA transporter (DAT) acts
as a vulnerability factor in PD. DAT-dependent re-uptake of DA
from the synaptic cleft is followed by intraneuronal DA metabo-
lism; this leads to the generation of oxidative free radicals, which
have potentially damaging effects, and dysregulation of this pro-
cess may contribute to neurodegeneration in PD. Neurotoxins that
are implicated as risk factors in clinical PD (Das et al., 2011; Mars-
den and Jenner, 1987), or are used in experimental PD (Section 3.1),
also have to enter DA neurons via DAT before exerting their dam-
aging effects on mitochondrial respiration, with concomitant
excessive generation of oxidative stress (Gainetdinov et al., 1997;
Miller et al., 1999). Therefore, it has been proposed that the protec-
tive effects of estradiol may be mediated by suppressive effects on
DAT (Dluzen, 2000). In accord with this hypothesis, we have shown
that in gonad-intact females striatal DAT levels are signiﬁcantly
higher at diestrous (low endogenous estradiol levels) compared
with proestrous (high endogenous estradiol levels) (Fig. 2A)
(McArthur et al., 2007), and this coincides with a greater depletion
of striatal DA when the neurotoxin is administered at proestrus
compared with diestrus (Datla et al., 2003) {McArthur, 2007
#715} (Yu and Liao, 2000). Furthermore, ovariectomy increased
Fig. 1. Hormonal inﬂuences on 6-OHDA-induced lesions in the nigrostriatal
dopaminergic pathway. Male and female rats underwent bilateral gonadectomy
(GDX) or sham operation (controls). While still under anaesthesia, animals received
a subcutaneous implant of slow release pellets containing estradiol (GDX + E2 to
replicate proestrous levels), 5a-dihydrotestosterone (GDX + DHT to replicate phys-
iological androgen levels) or a placebo pellet (GDX group). One week later all
animals received a unilateral injection of 1 lg 6-OHDA into the left medial forebrain
bundle and 2 weeks later tissue was collected for measurement of the lesion size in
the striatum (dopamine, DA, levels in the lesioned side expressed as a percentage of
levels in the contralateral, unlesioned side) or substantia nigra pars compacta, SNc
(the number of tyrosine hydroxylase immunoreactive, TH-IR, cells in the the
lesioned side expressed as a percentage of levels in the contralateral, unlesioned
side), as described in Table 1. Females: (A) GDX enhanced striatal DA loss and this
effect was reversed by E2, not DHT, whereas (B), the loss of TH-IR cells in the SNc
was unaffected by hormonal manipulations.Males: (C) GDX reduced striatal DA loss
and this effect was reversed by E2, not DHT, whereas (D), the loss of TH-IR cells in
the SNc was unaffected by hormonal manipulations. Values represent the
mean ± s.e.m. (n = 6). P < 0.05 versus gonad intact controls; #p < 0.05 versus
GDX. Full details in Murray et al. (2003) and McArthur et al. (2007).
Fig. 2. Effects of hormonal environment on striatal dopamine transporter (DAT)
levels in (A) female and (B) male rats. Bilateral gonadectomy (GDX) and hormone
treatments were performed as described in Fig. 1. Speciﬁc binding density of the
DAT ligand, [125I]-RTI 121, was assessed by autoradiography 1 week later. DAT
binding density was similar in control females at proestrus (Control Pro, high
endogenous estradiol) and control males, and these values were signiﬁcantly lower
than those found in diestrus females (Control Di, low endogenous estradiol) and
after GDX (males and females). Estradiol treatment (GDX + E2) suppressed DAT
binding density to proestrus levels in females and to control levels in males. Values
represent the mean ± s.e.m. (n = 6). P < 0.05 versus Control Pro (females), controls
(males) or GDX + E2 (males and females). Full details in McArthur et al. (2007).
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tion (Fig. 1A), with both effects being reversed by estradiol replace-
ment (Figs. 1A and 2A) (Murray et al., 2003; McArthur et al., 2007).
However, the DAT hypothesis does not hold true in males, and fails
to provide an explanation for sex differences in PD. For example,
striatal DAT levels in male rats were the same as those in females
at proestrus (Fig. 2), although 6-OHDA-induced striatal DA deple-
tion was signiﬁcantly greater when the toxin was administered
to gonad-intact males compared with female at proestrus
(Fig. 1A). Moreover, contrary to our prediction that castration in
males would induce a decrease in striatal DAT levels as an explana-
tion for the reduction in 6-OHDA-induced striatal lesions seen in
gonadectomised males (Fig. 1C), DAT binding density actually in-
creased (by20%) (Fig. 2B) {McArthur, 2007 #715}. It would follow
from these observations that the response of the NSDA to injury is
sexually dimorphic.5.2. Compensation versus neuronal survival
Depletion of striatal DA in PD is presumed to reﬂect degenera-
tion and loss of DAergic cells in the SNc, so one would expect that
the marked effects of gonadectomy and hormone treatments on
striatal DA lesions in experimental PD would be reﬂected by qual-
itatively similar changes in DA perikarya in the SNc. However, de-
spite the substantial evidence that systemic hormonal status
affects striatal DA loss (Sections 4.1 and 4.2; Fig. 1A and C), the sur-
vival of TH-IR cells in the partially lesioned SNc was unaffected in
either sex, whether animals were gonad-intact, gonadectomised or
gonadectomised and treated with estradiol, DHT or vehicle (Fig. 1B
and D) (McArthur et al., 2007; Moroz et al., 2003; Ferraz et al.,
2003, 2008). Additionally, estradiol failed to protect against 6-
OHDA-induced DA cell loss in primary, serum-free mesencephalic
cultures (Callier et al., 2002). These ﬁndings therefore suggest the
unexpected conclusion that the pronounced, yet qualitatively dif-
ferent effects of the sex hormone environment in males and fe-
males on toxin-induced striatal DA depletion must occur
independently of DAergic cell survival in the SNc.
The foregoing discussion raises two important questions: how
can the effects of physiological levels of circulating estradiol at
the nerve terminal of the partially injured NSDA system be disso-
ciated from effects at the level of the cell body in both sexes, and
why should the effects at striatal level be different in males and fe-
males? We have proposed that sexually dimorphic hormonal inﬂu-
ences on the activity of the neurons which survive in pre-clinical/
earlyPD, rather than on neuron survival per se, provides a compel-
ling explanation for these observations (McArthur et al., 2007;
Gillies and McArthur, 2010a,b). This concept is summarised in
Fig. 3, and supported by the following evidence.
In both clinical and experimental PD, the brain has a remarkable
capacity for compensation, and this is thought to account for the
fact that overt motor symptoms may not be apparent until around
80% of striatal DA and 60% of SNc DAergic perikarya are lost
(Bassilana et al., 2005; Bezard et al., 2001, 2003; Castaneda et al.,
1990; Song and Haber, 2000). The compensatory mechanisms are
complex and not fully understood, but are likely to involve
adaptations within the surviving DAergic neurons, such as
increased synthesis, metabolism and release of DA, to compensate
Fig. 3. Hypothetical schema for estrogenic inﬂuences on compensatory mechanisms in striatal terminals of surviving neurons in the damaged nigrostriatal dopaminergic
system. (A) As indicated by the arrows, in females, but not in males, estradiol (E2) enhances dopamine synthesis, release and turnover, whilst suppressing DAT levels and re-
uptake of the neurotransmitter from the synaptic cleft. (B) This preserves striatal function when lesion size is small/moderate (650%), but fails to do so as lesions increase,
allowing motor symptoms to become manifest. This action of E2 in females may render them more able to delay progression, or even onset, of disease.
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ioural studies indicates that females have an improved capacity
to recover from toxin-induced PD compared with males (Tamas
et al., 2005; Bourque et al., 2012), suggesting a sex difference in
the compensatory mechanisms. Furthermore, the sensitivity of
these compensatory mechanisms to sex hormone inﬂuences may
be sexually dimorphic. For example, in female, but not male ro-
dents, circulating estradiol (endogenous and exogenously given)
promotes basal, potassium- and amphetamine-stimulated striatal
DA release in vivo and in vitro (Becker, 1999; Dluzen, 2005; McDer-
mott et al., 1994; Ohtani et al., 2001; Pasqualini et al., 1995; Serova
et al., 2004; Xiao and Becker, 1998), and promotes in vivo stereo-
typic behaviours involving the NSDA system (Becker, 1999). Estra-
diol also increases DA turnover in females, but not in males, and is
more effective in the female compared with the male striatum in
suppressing the density of DAT (Fig. 2) (McArthur et al., 2007),
which critically regulates DAergic neuron dynamics. Estrogens
could be exerting these effects via direct actions on the DAergic
neurons themselves, but indirect effects on input circuitry are also
feasible. Of particular interest is the locus coeruleus, which is
known to inﬂuence the NSDA system and its adaptive response
to injury via noradrenergic transmission (Marien et al., 2004).
Notably, circulating estradiol has been reported to up-regulate
expression of TH (the rate-limiting enzyme for nor-adrenaline as
well as DA synthesis) in the female locus coeruleus, whereas in
males circulating testosterone down-regulates TH only after its
conversion to estradiol (Thanky et al., 2002). These sexually dimor-
phic hormonal responses have striking parallels with the effects of
hormonal manipulations on striatal DA depletion in experimental
PD (Section 4). Therefore, we propose that circulating gonadal
steroids, acting indirectly at the locus coeruleus to modify nor-
adrenergic regulation of the NSDA system in a sex-speciﬁc manner,
offers a potential mechanisms to explain why the effects of
estradiol on 6-OHDA-induced striatal DA loss is different in males
and females (Gillies and McArthur, 2010a). Other sexuallydifferentiated, estrogen-sensitive networks which could modify
adaptations of the NSDA system to injury include the mesocortical
DAergic pathway (Kritzer and Creutz, 2008) and the serotonergic
system of the dorsal raphe (Klink et al., 2002). Further studies
are needed to establish the role of these systems in clinical and
experimental PD.
Collectively, these ﬁndings demonstrate that in females, estro-
gens have a positive effect on mechanisms underpinning compen-
satory processes in the injured NSDA, which could thus explain
why estradiol appears neuroprotective at the level of DAergic ter-
minals, but not the perikarya. The failure of estradiol to have such
effects in male rodents is compatible with its failure to protect
against striatal lesions in this sex (Murray et al., 2003; Gao and
Dluzen, 2001; Disshon and Dluzen, 2000), and suggests mecha-
nisms which could underpin sex differences in PD.
5.3. Innate sex differences in NSDA and related circuitry
Similar to the human NSDA system (discussed in Section 2.2),
biological sex differences are also present in the rodent NSDA
system. This is supported by studies showing sex differences in
hormonal responsiveness of NSDA circuitry, described above
(Section 5.2). Additionally, the male SNc contains signiﬁcantly
more DA neurons with a different topographical organisation com-
pared to the female SNc (Dewing et al., 2006; Murray et al., 2003;
McArthur et al., 2007). Yet, despite these structural differences, no
sex differences are reported for striatal DA content and basal
extracellular striatal DA levels, which are thought to be maintained
by sex differences in neuronal dynamics (Murray et al., 2003;
Robinson et al., 1990; Walker et al., 2000; Ji and Dluzen, 2008;
Virdee et al., 2013). However, amphetamine-stimulated DA release
and DA-dependent motor responses are signiﬁcantly greater in
females compared with males (Becker, 1999; Virdee et al., 2013),
indicating functional differences when the system is activated.
Interestingly, equalisation of male and female circulating sex
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extracellular striatal DA levels, which were absent in the gonad-
intact animals (Walker et al., 2000). This suggests that there are
fundamental sex differences in the organisation of the NSDA-
associated circuitry, which are independent of the adult sex
hormone environment.
The origins of sex dimorphisms in the NSDA system have
received relatively little attention, but the organisational actions
of gonadal hormones during development, as well as genetic
factors (see Section 6.1), are likely to have important inﬂuences
(Dewing et al., 2006; Gillies et al., 2004; Gillies and McArthur,
2010b; Vadasz et al., 1985, 1988). Regarding hormonal factors, it
is well established that a transient perinatal rise in testosterone
production by the developing testes is a principal factor in the
masculinisation/defeminisation of rodent brain regions controlling
reproduction and reproductive behaviours (McCarthy, 2008;
Wilson and Davies, 2007; Arnold and Breedlove, 1985). Most
evidence for this concept relates to the hypothalamus, which has
been the prototype for studying brain sex differences. Signiﬁcantly,
the sexually differentiating effect of testosterone in the brain
occurs largely after its conversion to estradiol by brain aromatases.
This early exposure to estradiol is thought to result in a loss of
capacity of the male brain to respond to estradiol in later life,
whereas the female brain retains this responsiveness to estradiol,
as manifest by the ability of estradiol to stimulate ovulation by po-
sitive feedback effects within the hypothalamo–pituitary–gonadal
axis. Hence, defeminisation of the brain has also been deﬁned as a
loss of capacity to respond to oestrogens (McCarthy, 2008). Inter-
estingly, one study reported that neonatal treatment of female rats
with testosterone, to mimic the transient elevations occurring nat-
urally in males, compromised the protective effect of estradiol in
the 6-OHDA model of PD (Moroz et al., 2003). These observations
support the notion that the adult male NDSA system, whether
intact or injured, may also lose its capacity to respond to estradiol
as a result of early exposure to estradiol after aromatisation of
testosterone. This intriguing mechanism, which could explain the
sex dimorphism in estrogen’s ability to protect against striatal
DA depletion in experimental PD, remains to be fully tested.5.4. Estrogenic signalling
Thus far, we have considered ways in which physiological levels
of sex hormones, particularly estradiol, differentially inﬂuence
adaptive/compensatory mechanisms in the partially injured NSDA
in males and females, thereby affecting striatal DA levels, but not
DAergic cell numbers in the SNc (Sections 2.3.3 and 4). Such mech-
anisms of estrogenic protection relate speciﬁcally to situations
where NSDA lesion size is mild/moderate and will be unique to
PD, rather than being more widely applicable to other forms of
brain injury. However, estradiol also exerts more generally ac-
claimed neuroprotective actions which can prevent cell loss in
many types of brain injury. These include ischaemia, trauma, infec-
tion and neurodegeneration, where estrogens can activate various
non-speciﬁc processes involved in cell survival, such as mitochon-
drial function, anti-oxidant activity and effects on gene products
involved in regulating apoptosis. These mechanisms, along with
considerations of whether estradiol’s protective effects involve
the classical nuclear estrogen receptors (ER), ERa or ERb, or the
more recently recognised G protein-coupled receptor, GPER1 (also
termed GPR30), are covered in many extensive reviews (Bourque
et al., 2012; McEwen and Alves, 1999; Brann et al., 2007; Wise
et al., 2001; Garcia-Segura et al., 2001; Raz et al., 2008; Behl,
2002; Green and Simpkins, 2000). Therefore, here we shall
comment only on the relatively sparse information which may be
relevant to PD and sex differences.Whether or not estradiol protects against SNc DAergic cell loss
in experimental PD appears to vary with the neurotoxin used, the
severity of the lesion, the strain and species of rodent and the treat-
ment regimen (dose of estrogen used; period of hypoestrogenicity
between ovariectomy and treatment), as well as sex (Gillies and
McArthur, 2010a; Ferraz et al., 2008; Cordellini et al., 2011; Brin-
ton, 2008; McArthur and Gillies, 2011). For example, in our proto-
col, where estradiol failed to prevent SNc DA cell loss, the steroid
was replaced at the time of ovariectomy using slow release im-
plants to provide proestrus levels (circa 200 pmol estradiol/ml);
unilateral injections of 1 lg 6-OHDA were given 1 week later to
produce a mild/moderate lesion, followed by a 2 week interval
for the lesion to develop before tissue was collected for analysis
(Murray et al., 2003; McArthur et al., 2007) (Fig. 1, Section 4.1).
In contrast, another study reported signiﬁcant protection at both
SNc and striatal levels when using commercially ovariectomised
rats; after an undeﬁned period of hypogenicity, a bolus injection
of estradiol (20 lg s.c.) was administered 24 h prior to unilateral
injections of 8 lg 6-OHD to produce a very large lesion (>90% loss
of striatal DA and >60% loss of SNc DAergic neurons) (Quesada
et al., 2008). These comparisons highlight the complexity of estro-
genic protective effects and our present inability to reach a simple
consensus regarding the issue of hormonal protection in PD. How-
ever, the work by Quesada and colleagues (Quesada et al., 2008),
using female rats, demonstrated that DA cell survival was depen-
dent on estradiol acting via the IGF-1 system operating through
the phosphatidylinositol 3-kinase (PI3K)/Akt (PKB) pathway,
which modulates expression of anti-apoptoic (Bcl-2) and apoptotic
(Bad, Bax) proteins to promote cell survival. This is in agreement
with reports of the importance of IGF-1 as a mediator of estrogenic
neuroprotection in many circumstances (Mendez et al., 2005).
However, it remains to be determined whether sex differences
exist in estrogenic neuroprotection mediated via IGF-1 and its
down-stream signalling. Indeed, this should not be ruled out,
because evidence suggests that intracellular signalling pathways
may be sexually differentiated as a result of perinatal exposure
to raised endogenous estradiol levels, after aromatisation of
testosterone, in males, at least in the hypothalamus (Abraham
and Herbison, 2005; Auger et al., 2001).
Interesting sex differences have, however, been noted in the
expression of molecules associated with cell survival pathways,
both in the intact and injured SNc. For example, compared with
males, female C57Bl/6 mice possess greater Bcl-2/Bax and
glutathione/glutathione disulphide ratios in the striatum, suggest-
ing a balance of pro-survival and anti-oxidant factors, respectively,
to favour an inherent superior neuroprotective capacity
(Rodriguez-Navarro et al., 2008). Sex differences have also been
reported in the striatum for the temporal expression of molecular
pathways involved in cell survival as the DA response to the
neurotoxin, MA, develops over 3 days (Bourque et al., 2011). Hence,
an initial fall in striatal levels of DA and phosphorylated Akt in both
sexes (30 min after MA injection) was associated in females, but
not in males, with increases in levels of extracellular signal-
regulated kinase (ERK1/2) (30 min), Akt (day 1) and phosphoryla-
tion on serine 9 of glycogen synthase kinase 3b (GSK3b; day 1
and 3); by day 3 DA levels had risen signiﬁcantly in females,
whereas they remained signiﬁcantly lower in males. Activation of
GSK3b, a constitutively active kinase, is associated with neuronal
apoptosis caused by oxidative stress (Gomez-Sintes et al., 2011),
which is a key neuropathological process in clinical and experi-
mental PD (Phani et al., 2012). Both the PI3K/Akt and the ERK1/2
pathways converge downstream on GSK3b to inhibit its activity
by phosphorylation on serine 9 (Manning and Cantley, 2007).
Together, the sex-speciﬁc striatal molecular patterns following
MA administration suggest a reduction in GSK3b activity in
females, favouring recovery in females, but not in males. However,
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be determined, as does the relevance of the striatal data for nigral
cell loss. An effect at the level of the DA neuron is supported by the
ﬁnding that GSK3b activation (via Ser 9 dephosphorylation) medi-
ated 6-OHDA-induced death in susceptible cell lines (Chen et al.,
2004). Additionally, a recent study using male rats reported that
intrastriatal injection of 6-OHDA led to activation of GSK3b and
caspase 3 in SNc DA neurons, suggesting activation of the intrinsic
(mitochondrial) pathway of apoptosis (Hernandez-Baltazar et al.,
2013). Future studies investigating the inﬂuences of sex steroids
on these pathways in females as well as males will provide impor-
tant insight into sex differences in PD and the potential for sex-
speciﬁc therapies.
In the monogenetic forms of PD, mutations frequently occur in
genes encoding proteins that localise to the mitochondria, includ-
ing PINK-1, DJ-1, a-synuclein and LRRK2 (Canet-Aviles et al., 2004;
Devi et al., 2008; Gautier et al., 2008; Papkovskaia et al., 2012).
Deregulation of mitochondrial function has also been linked to
sporadic forms of PD, either as a potential direct cause or indirect
consequence of neuronal damage. The contribution of mitochon-
drial dysfunction to DAergic degeneration is corroborated in tox-
in-induced animal models of PD (Dexter and Jenner, 2013),
supporting the view that mitochondrial regulation of cell survival
molecules (including those discussed above) and apoptosis is com-
promised in PD. Interestingly, in non-neuronal cell lines ER ligands
can inﬂuence the intrinsic (mitochondrial) apoptotic pathway, as
well as the extrinsic apoptotic pathway, and this depends on their
relative afﬁnities for ERa and ERb and the ratio of expression of
ERa:ERb within the cells (Pons et al., 2013; Chen and Chien,
2013). Moreover, mitochondrial ERa and ERb have been shown
to act in co-operation with the nuclear ERs to regulate the mito-
chondrial respiratory chain (Chen et al., 2009). Thus, although
sex differences in mitochondrial function have not yet been linked
to a sex bias in PD, the observation that apoptotic mechanisms are
sensitive to prevailing levels of sex hormones suggests that such a
possibility merits further investigation.
Sex differences in the levels of ERs within the NSDA pathway
could potentially underlie sex differences in estrogenic signalling
pathways. Separate studies using the same antibody reported that
ERb was absent in the male mouse SNc (Shughrue, 2004), but
weakly expressed in the female SNc (Mitra et al., 2003; Merchent-
haler et al., 2004); the striatum appears not to express ERb
(Shughrue, 2004). ERa was not found in the DAergic neurons of
the SNc and its expression in the striatum is low, although possibly
at a higher level in female compared with male mice (Rodriguez-
Navarro et al., 2008). Current evidence therefore provides minimal
support for sex differences in ER expression, and supports the view
that estrogens may act indirectly or via nuclear receptor-
independent mechanisms to inﬂuence DAergic neurons. Support-
ing this view, single sex studies using ER selective ligands or ER
null and wild type mice found that ERa, ERb and GPER1 play a role
in estrogenic neuroprotection, with ERa possibly playing the more
dominant role (Al-Sweidi et al., 2011; Bourque et al., 2013; Baraka
et al., 2011). Further studies are needed to determine whether
selective ligands may exert sex-speciﬁc effects.
6. Genes, environment and sex differences in experimental
Parkinson’s disease
6.1. The SRY gene
The results discussed above (Section 5, Table 1, Fig. 1) demon-
strate that, although there is a clear sex difference in the survival
of SNc DAergic neurons in experimental models of the pre-clini-
cal/early stages of PD, this occurs independently of sex hormone
inﬂuences (McArthur et al., 2007; Moroz et al., 2003). The originsof these differences remain unknown. However, in the intact adult
SNc, we and others have reported that the numbers of DAergic
neurons are signiﬁcantly greater in male rats and mice compared
with female rodents by 20% (Dewing et al., 2006; Murray et al.,
2003; McArthur et al., 2007). This is perhaps surprising, consider-
ing the fact that a greater percentage of cells are lost in the male
SNc compared to females. A possible explanation could be the exis-
tence of a heterogeneous population of cells within the SNc, a no-
tion supported by the observation that there are regional
differences in resistance or resilience of DAergic cells in rodent
models of PD, as well as in PD patients (Gillies et al., 2004; McAr-
thur et al., 2007; Damier et al., 1999; Carman et al., 1991). A greater
proportion of resilient cells in females and/or a lower proportion of
this resilient population in males are thus plausible explanations
for sex differences in PD.
Our own studies rule out the possibility that sex hormones play
a signiﬁcant role in determining the size of the adult DAergic pop-
ulation in the SNc. Hence, we have shown that neither adult gonad-
ectomy nor neonatal gonadectomy of newborn male rats, with or
without the masculinising inﬂuence of neonatal treatment with
DHT or estradiol, affects the adult DAergic neuron count (Gillies
et al., 2004; McArthur et al., 2007). Nigral cell number does, how-
ever, appear to depend on expression of SRY coded by the Y chro-
mosome, which has been co-localised in a subset of male SNc DA
neurons (Dewing et al., 2006). Silencing of the SRY gene in the male
rodent SNc reduces the DA neuron number to that of females and
induces motor deﬁcits. These ﬁndings therefore support the
emerging concept that factors encoded by the sex chromosome
genes, as well as sex hormones, contribute to sexual differentiation
of the brain (Arnold and Burgoyne, 2004; Arnold, 2012). It remains
to be determined whether SRY inﬂuences susceptibility of DA neu-
rons to injury, but it does represent an interesting non-hormonal
candidate responsible for sex differences affecting DAergic cell loss
in the SNc, at least in experimental PD.6.2. Stress and early life adversity
The impact of adverse environments in experimental PD is an
understudied area. Our preliminary evidence suggests that expo-
sure of adult rats to immobilisation stress exacerbates striatal
and nigral lesions produced by 6-OHDA in males, but not in fe-
males (unpublished observations, Allen, Buckingham, Gillies &
Dexter). In addition, studies performed in male animals suggest
that exposure to environmental stressors in early life puts the mid-
brain DAergic neuronal population at risk in later life.
For example, perinatal exposure to inﬂammatory stimuli (lipo-
polysaccharide, the bacterial endotoxin), obstetric complications,
pesticides and iron-enriched diets, may themselves alter adult
midbrain DAergic neuron number and activity, and/or enhance
their susceptibility to subsequent challenges, including exposure
to 6-OHDA (Wang et al., 2009; Barlow et al., 2007; Ling et al.,
2004; Boksa, 2004; Boksa and El-Khodor, 2003). In addition, neona-
tal separation of male rat pups from their mothers exacerbated the
toxic effects of 6-OHDA on locomotor activity and striatal TH
expression in adulthood (Pienaar et al., 2008). As responses both
to acute and chronic stressors in adulthood and to early-life adver-
sity are sex-speciﬁc (Kudielka and Kirschbaum, 2005), the impact
of stress throughout life for developing PD, as well as being a po-
tential source of sex differences in PD susceptibility, requires
attention.7. A role for glia
Astrocytes and microglia are the major glial cell types in the
brain and comprise 80–90% of the total brain cellular population
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maintaining CNS neurotransmission and homeostasis, as well as
mounting innate immune responses aimed at protecting the brain
against insults such as physical trauma, ischaemia, infection and
neurodegenration (Klegeris et al., 2007; Halassa and Haydon,
2010). In the early, activation stage of the innate immune response,
microglia and to a lesser extent, the astrocytes, produce oxidative
and pro-inﬂammatory (potentially harmful) mediators; this trig-
gers the later, resolution phase of the immune response, involving
production of anti-inﬂammatory (protective) factors as well as the
induction of phagocytic microglia, a phenotype essential for clear-
ance of dying or dead cells and termination of the inﬂammatory re-
sponse (Farina et al., 2007; Minghetti, 2005; Lucas et al., 2006).
However, excessive or chronic glial activation and/or failure to re-
solve the neuroinﬂammatory response can become damaging and
can exacerbate on-going disease processes, including those relat-
ing to PD (Rogers et al., 2007; McGeer and McGeer, 2008; Barres,
2008). It remains a highly controversial issue as to whether
microglial inﬂammation is a bystander effect of PD-related neuro-
toxicity or a primary pathogenic process, but animal experimental
studies as well as investigations of post-mortem tissues identify
microglial activation and neuroinﬂammation as an early biomarker
for disease (Chung et al., 2009; Lundblad et al., 2012). Control of
glial activity is thus an attractive target for novel neuroprotective
strategies. Furthermore, emerging evidence suggests that the cen-
tral neuro-immune response is sexually dimorphic (Schwarz and
Bilbo, 2012; Santos-Galindo et al., 2011). Glial cells should, there-
fore, be considered as contributory factors to sex differences in PD.7.1. Astrocytes
Studies of speciﬁc hypothalamic nuclei demonstrate that astro-
cytes are sexually differentiated in adulthood in terms of their
morphological complexity, cell signalling mechanisms, plasticity
and hormone responsiveness, especially to estradiol (McCarthy,
2008; Naftolin et al., 2007; Kuo et al., 2010). These sex dimor-
phisms are programmed neonatally by testosterone after conver-
sion to estradiol, and suppress the ability of the adult
hypothalamic circuitry to respond to estrogen priming of the
gonadotrophin releasing hormone/luteinising hormone surge,
which is essential to trigger ovulation. Whether astrocytes are sim-
ilarly sexually differentiated in other adult brain regions is an
important question that needs to be addressed. However, develop-
ing astrocytes from many brain regions show sex-speciﬁc charac-
teristics. For example, primary cortical astrocyte cultures from
newborn male mice and hormonally masculinised newborn fe-
males produce a greater cytokine response when challenged with
the bacterial endotoxin, lipopolysaccharide, compared with normal
female astrocytes, indicating that sex differences in the neuroim-
mune response may be predetermined by perinatal testosterone
exposure (Santos-Galindo et al., 2011). When challenged with
MPTP, astrocyte cultures derived from the neonatal male mouse
mesencephalon also responded with a greater elevation in oxida-
tive stress levels compared with female mesencephalic astrocytes
or cortical astrocytes of either sex (Sundar Boyalla et al., 2011),
suggesting that the glial response to neurodegenerative processes
is both sex- and brain region-speciﬁc, and is most robust in the
NSDA system. In adult mice, MPTP administration increased stria-
tal expression of the astrocyte-speciﬁc marker, glial ﬁbrillary acidic
protein (GFAP) in both sexes, but a time-course study over 21 days
revealed a more sustained activation in females (Ciesielska et al.,
2009). Although the functional implications require further study,
the data suggest that in males astrocytes may generate a greater,
potentially harmful, neuro-inﬂammatory response, whereas in fe-
males astrocytes contribute compensatory and survival-promotingproperties, favouring more efﬁcient recovery mechanisms, which,
together, may contribute to sex differences in PD.
It has long been acknowledged that, across species, there are
sex differences in the peripheral immune system. To a large extent,
this has been attributed to gonadal hormones, especially estradiol,
which augments aspects of immune activity (Schwarz and Bilbo,
2012; Nadkarni and McArthur, 2013). Gonadal hormones also reg-
ulate glial response to injury (Arevalo et al., 2013) and, to a large
extent, the neuroprotective actions of circulating estradiol are
dependent on its powerful anti-inﬂammatory actions on astrocytes
(Garcia-Ovejero et al., 2005; Marchetti et al., 2005; Vegeto et al.,
2008). Hence estradiol treatment of midbrain astrocytes in vitro re-
duces the production of cytokines and inﬂammatory mediators in
response to inﬂammatory stimuli (Vegeto et al., 2008; Kipp et al.,
2007), and in vivo circulating estradiol down-regulates astrocyte
activation in parallel with its protective effects in female mice trea-
ted with MPTP (Morale et al., 2006). The effect of androgens on
glial activity has received relatively little attention. Available data
are contradictory, with evidence for both protective and detrimen-
tal effects, depending on the type of injury, among other factors
(Arevalo et al., 2013), although the effects on astrocytes in PDmod-
els has not been reported. On balance, the available evidence
would support the view that astrocytes are important targets for
circulating estrogens, which could contribute to sex differences
in PD.
In addition to responding to estrogens, astrocytes are capable of
synthesising estradiol. In response to injury, aromatase expression
is induced de novo in astrocytes, enabling relatively high levels of
estradiol to be synthesised locally and exert a variety of protective
effects on vulnerable neurons (Azcoitia et al., 2010). Although this
response occurs in both males and females, recent evidence sug-
gests that it occurs more rapidly and robustly in females (Liu
et al., 2007; Mirzatoni et al., 2010), further suggesting a mecha-
nism which could explain the smaller lesion size and faster recov-
ery in females which characterises many types of brain injury,
including PD.
Evidence for constitutive expression of ERs in astrocytes is
contradictory but, similar to the situation for aromatase, receptor
up-regulation, especially for ERa, appears to be a key part of the
neural response to many types of brain injury in rodent and pri-
mates (Garcia-Ovejero et al., 2005; Blurton-Jones and Tuszynski,
2001). This phenomenon has not been speciﬁcally reported for
the damaged NSDA system, but, notably, a marked increase in
GPER1 was seen in the striatum of male, but not female, mice
7 days after exposure to methamphetamine (Bourque et al.,
2011). The speciﬁc cell type mounting this response was not iden-
tiﬁed, and the signiﬁcance remains to be determined. However,
the GPER1 selective agonist, G1, has been reported to protect
against MPTP-induced striatal toxicity (Bourque et al., 2012)
and, as the G1 ligand lacks estrogenic activity in reproductive tis-
sues, such observations merit further investigation for therapeutic
potential (Otto et al., 2009).
Taking the astrocyte response to injury as a whole, it would
thus appear that central estrogenic activity could critically regulate
progression of the astrocytic activation and resolution through the
neuro-inﬂammatory cascade. Hence, the initial response to a chal-
lenge, involving the release of pro-inﬂammatory cytokines, chemo-
kines and reactive oxygen/nitrogen species, may be primed by
circulating estradiol and is necessary for local resistance and repair
mechanisms; this is closely associated with an up-regulation of
astrocytic estradiol synthesis (aromatase), as well as astrocytic
responsiveness to estrogens (ERs)and astrogliogenesis (prolifera-
tion and increased GFAP expression), which achieves a local estro-
genic environment capable of preventing over-activation of the
neuro-immune response and exacerbation of neural damage,
whilst also exerting its protective effects on adjacent neurons.
Fig. 4. Estradiol enhances microglial phagocytosis. Co-cultures of the murine microglial BV2 cell line and the dopamine-producing neuron-like PC12 cells were used as a
model to investigate hormonal inﬂuences on microglial phagocytosis of apoptoic neurons (McArthur et al., 2010). (A) Treatment of BV2 microglia for 16 h with 100nM 17b-
estradiol had no effect on the phagocytosis of vehicle-treated, non-apoptotic PC12 cells, but signiﬁcantly increased the number of microglia phagoytosing apoptotic 6-OHDA-
treated PC12 cells. P < 0.05 versus untreated BV2 cells. (B) Example of BV2 microglia phacocytosing CMFDA-labelled green ﬂuorescent PC12 cell treated with 6-OHDA.
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contribute to sex differences in PD.7.2. Microglia
Data on sex differences in the numbers or activity of microglia
in the adult brain are sparse, but developmental studies suggest
that they may be profound, with signiﬁcance for brain disorders.
For example, at postnatal day 4, the numbers of microglia in the
male rat hippocampus, parietal cortex and amygdala are signiﬁ-
cantly greater than those seen in females (Schwarz and Bilbo,
2012). This has been proposed to lead to a fundamentally different
neuro-immune response to early-life immune challenge, which has
been related to long-term, profound changes in microglial function
and cognitive behaviours in males, but not females. Microglia are
thought to contribute to DAergic cell damage in clinical and exper-
imental PD (Halliday and Stevens, 2011; McGeer and McGeer,
2008; Orr et al., 2005; L’Episcopo et al., 2010), but whether sexual
differentiation of NSDA microglia contributes to sex differences in
PD remains to be determined. However, similar to astrocytes, go-
nadal steroids are powerful regulators of microglial numbers and
reactivity in many circumstances (Arevalo et al., 2013). Of rele-
vance to PD, it has been demonstrated that activation of microglia
with LPS can cause the death of DAergic neurons in cultures of pri-
mary mesencephalic neurons or DAergic cell lines through the re-
lease of toxic factors such as reactive oxygen/nitrogen species and
TNFa (Liu et al., 2005; McArthur et al., 2010), and this can be pre-
vented by co-treatment of the microglia with estradiol (Liu et al.,
2005). Studies in vivo also showed that administration of estradiol
to ovariectomised mice treated with MPTP suppressed iNOS and
nitric oxide production by microglia and protected against striatal
DA loss (Morale et al., 2006). In addition to suppressing the poten-
tially harmful phenotype induced by injury, our preliminary data
suggest that estradiol can also promote microglial phagocytosis
of DAergic PC12 cells rendered apoptotic by 6-OHDA treatment
(Fig. 4; McArthur, Vohra, Solito & Gillies, unpublished observa-
tions); this occurs via ERb signalling, whereas GPR30 signalling
may suppress microglial phagocytic activity, whilst promoting cell
cycle progression and cell proliferation (Vohra et al., 2012), a prop-
erty of this receptor which has been reported in other tissues
(Prossnitz et al., 2008).8. Conclusions
In this review we have summarised the clinical and experimen-
tal evidence which demonstrates that males have a greater suscep-
tibility to PD, compared with females. Compelling evidence
suggests that biological sex differences in the NSDA pathway
may underlie these differences in vulnerability, and could also ac-
count for the sexually dimorphic actions of estradiol, which pro-
tects females against striatal DA loss in experimental PD, but
fails to protect, or may even worsen, striatal lesions in males. These
ﬁndings open up the potential to exploit hormone-based therapies
as a novel approach to develop treatments which can delay, and
possibly halt, progression of the disease. Such disease modifying
strategies are urgently needed to supersede current treatments
relying on DA replacement strategies, which can only ameliorate
symptoms. The ﬁndings also highlight the need for sex-speciﬁc
medicines, which demands a better understanding of sex dimor-
phisms in the intact and injured NSDA. This will also require inves-
tigation into how the internal hormonal milieu interacts with other
sex-speciﬁc factors, including differential exposure to potentially
neurotoxic agents, as well as the impact of SRY gene expression
within SNc DAergic neurons. Although PD research has classically
focussed on the NSDA system, other pathways showing signs of
pathologic change prior to those in the NSDA are receiving growing
attention and may help to explain the non-motor symptoms
(Dexter and Jenner, 2013; Jenner et al., 2013; Bronstein et al.,
2009). Therefore, as our concept of PD is evolving, future studies
on sex differences in the prevalence and nature of PD should
spread the net wider.
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